Voloridge Investment Management
RVNC

Voloridge Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Voloridge Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-271,852
Closed -$2.39M – 1392
2023
Q4 		$2.39M Sell
271,852
-272,595
-50% -$2.23M 0.01% 791
2023
Q3 		$6.24M Buy
544,447
+113,351
+26% +$2.18M 0.03% 590
2023
Q2 		$10.9M Buy
431,096
+266,070
+161% +$8.29M 0.05% 438
2023
Q1 		$5.32M Sell
165,026
-94,427
-36% -$2.94M 0.03% 649
2022
Q4 		$4.79M Sell
259,453
-289,154
-53% -$6.61M 0.03% 655
2022
Q3 		$14.8M Buy
548,607
+245,531
+81% +$4.98M 0.08% 334
2022
Q2 		$4.19M Buy
303,076
+96,271
+47% +$1.48M 0.02% 742
2022
Q1 		$4.03M Sell
206,805
-12,238
-6% -$186K 0.02% 711
2021
Q4 		$3.58M Buy
+219,043
New +$3.65M 0.02% 843
2020
Q2 		– Sell
-13,757
Closed -$204K – 1558
2020
Q1 		$204K Buy
+13,757
New +$285K 0.01% 948
2019
Q4 		– Sell
-19,522
Closed -$254K – 1397
2019
Q3 		$254K Buy
+19,522
New +$239K ﹤0.01% 963
2019
Q2 		– Sell
-20,151
Closed -$318K – 1140
2019
Q1 		$318K Buy
+20,151
New +$349K 0.01% 789

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Voloridge Investment Management's RVNC Position: Q1 2024 in Review

Voloridge Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 271,852 shares — an estimated $2.39M sold.

Voloridge Investment Management first reported a position in RVNC in Q1 2019 and held it in 12 quarters. The position peaked at $14.8M in Q3 2022. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Voloridge Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 271,852 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $2.39M.
  • Voloridge Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 12 quarters.
  • Voloridge Investment Management's Revance Therapeutics, Inc. position peaked at $14.8M in Q3 2022.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Voloridge Investment Management's 13F filing for Q1 2024, filed 15 May 2024.